Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
2
-glycoprotein-I in 500 women with recurrent miscarriage: results of
a comprehensive screening approach. Hum Reprod 1995; 10: 200105.
24 Yetman DL, Kutteh WH. Antiphospholipid antibody panels and
recurrent pregnancy loss: prevalence of anticardiolipin antibodies
compared with other antiphospholipid antibodies. Fertil Steril 1996;
66: 54046.
25 Silver RM. Fetal death. Obstet Gynecol 2007; 109: 15367.
26 Smith GCS, Crossley JA, Aitken DA, et al. First-trimester placentation
and the risk of antepartum stillbirth. JAMA 2004; 292: 22492254.
27 Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid
antibodies and fetal death. Obstet Gynecol 1996; 87: 48993.
28 Meis PJ, Goldenberg RL, Mercer BM, et al, for the Maternal-Fetal
Medicine Units Network of the National Institute of Child Health
and Human Development. The preterm prediction study: risk
factors for indicated preterm births. Am J Obstet Gynecol 1998;
178: 56267.
29 Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies
cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep
2007; 9: 21925.
30 Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA,
Hughes GRV. Central nervous system involvement in the
antiphospholipid (Hughes) syndrome. Rheumatology 2003;
42: 20013.
31 Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR,
Chinn R, Isenberg DA. A longitudinal study of anticardiolipin
antibody levels and cognitive functioning in systemic lupus
erythematosus. Arthritis Rheum 1999; 4: 73541.
32 Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of
cognitive function and anticardiolipin antibodies in systemic lupus
erythematosus. Arthritis Rheum 1999; 42: 72834.
33 Tektonidou MG, Varsou N, Kotoulas G, Antoniou A,
Moutsopoulos HM. Cognitive decits in patients with
antiphospholipid syndrome: association with clinical, laboratory,
and brain magnetic resonance imaging ndings. Arch Intern Med
2006; 166: 227884.
34 Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ,
Hughes GRV. Can neurologic manifestations of Hughes
(antiphospholipid) syndrome be distinguished from multiple
sclerosis?: Analysis of 27 patients and review of the literature.
Medicine 2000; 79: 5768.
35 Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the
antiphospholipid syndrome: recommendations for treatment.
Committee consensus report. Lupus 2003; 12: 51823.
36 Amigo MC, Garcia-Torres R, Robles M, Bochicchio T, Reyes PA.
Renal involvement in primary antiphospholipid syndrome.
J Rheumatol 1992; 9: 18185.
37 Tektonidou MG, Sotsiou F, Nakopoulou L,
Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid
syndrome nephropathy in patients with systemic lupus
erythematosus and antiphospholipid antibodies: prevalence,
clinical associations, and long-term outcome. Arthritis Rheum
2004; 50: 256979.
38 Paul SN, Sangle SR, Bennett AN, et al. Vasculitis, antiphospholipid
antibodies, and renal artery stenosis. Ann Rheum Dis 2005;
64: 180002.
39 Francs C, Niang S, La tte E, Pelletier F, Costedoat N, Piette JC.
Dermatologic manifestations of the antiphospholipid syndrome:
two hundred consecutive cases. Arthritis Rheum 2005; 52: 178593.
40 Asherson RA, Cervera R, de Groot PG, et al. Catastrophic
antiphospholipid syndrome: international consensus statement on
classication criteria and treatment guidelines. Lupus 2003;
12: 53034.
41 Branch DW, Khamashta MA. Antiphospholipid syndrome:
Obstetric diagnosis, management and controversies. Obstet Gynecol
2003; 101: 133344.
42 Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal
booking: systematic review of controlled studies. BMJ 2005; 330: 565.
43 Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD.
Elevated antiphospholipid antibody titers and adverse pregnancy
outcomes: analysis of a population-based hospital dataset.
BMC Pregnancy Childbirth 2009; 9: 1119.
44 Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP,
Lockshin MD. High thrombosis rate after fetal loss in
antiphospholipid syndrome: eective prophylaxis with aspirin.
Arthritis Rheum 2001; 44: 146667.
45 Wilson WA, Gharavi AE, Koike T, et al. International consensus
statement on preliminary classication criteria for denite
antiphospholipid syndrome: report of an international workshop.
Arthritis Rheum 1999; 42: 130911.
46 Miyakis S, Lockshin MD, Atsumi T, et al. International consensus
statement on an update of the classication criteria for denite
antiphospholipid syndrome (APS). J Thromb Haemost 2006;
4: 295306.
47 Lackner KJ, Peetz D, von Landenberg P. Revision of the Sapporo
criteria for the antiphospholipid syndromecoming to grips
with evidence and Thomas Bayes? Thromb Haemost 2006;
95: 91719.
48 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are
stronger risk factors for thrombosis than anticardiolipin antibodies
in the antiphospholipid syndrome: a systematic review of the
literature. Blood 2003; 101: 182732.
49 Martnez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, et al.
Transiently positive anticardiolipin antibodies do not increase the
risk of thrombosis in patients with systemic lupus erythematosus.
Lupus 2007; 16: 81016.
50 Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between
antiphospholipid antibodies and recurrent fetal loss in women
without autoimmune disease: a metaanalysis. J Rheumatol 2006;
33: 221421.
51 Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I,
antiprothrombin antibodies, and the risk of thrombosis in the
antiphospholipid syndrome. Blood 2003; 102: 271723.
52 Galli M, Borrelli G, Jacobsen EM, et al. Clinical signicance of
dierent antiphospholipid antibodies in the WAPS (warfarin in the
antiphospholipid syndrome) study. Blood 2007; 110: 117883.
53 Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study
of antibodies to beta2-glycoprotein I and prothrombin, and risk of
thrombosis. J Thromb Haemost 2005; 3: 123138.
54 Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S.
Antibody proles for the diagnosis of antiphospholipid syndrome.
Thromb Haemost 2005; 93: 114752.
55 Ruatti A, Calligaro A, Hoxha A, et al. Laboratory and clinical
features of pregnant women with antiphospholipid syndrome and
neonatal outcome. Arthritis Care Res 2010; 62: 30207.
Seminar
1508 www.thelancet.com Vol 376 October 30, 2010
56 Pengo V, Ruatti A, Legnani C, et al. Clinical course of high-risk
patients diagnosed with antiphospholipid syndrome.
J Thromb Haemost 2010; 8: 23742.
57 Giannakopoulos, Passam F, Ioannou Y, Krilis SA. How we diagnose
the antiphospholipid syndrome. Blood 2008; 113: 98594.
58 de Laat B, Derksen RH, Urbanus RT, De Groot PG. IgG antibodies
that recognize epitope Gly40-Arg43 in domain I of beta
2-glycoprotein I cause LAC, and their presence correlates strongly
with thrombosis. Blood 2005; 105: 154045.
59 de Laat B, Pengo V, Pabinger I, et al. The association between
circulating antibodies against domain I of beta2-glycoprotein I and
thrombosis: an international multicenter study. J Thromb Haemost
2009; 7: 176773.
60 Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated
pathogenic mechanism in the antiphospholipid syndrome: role in
pregnancy losses and thrombosis. Lupus 2010; 19: 46069.
61 Giannakopoulos B, Krilis SA. How I treat the antiphospholipid
syndrome. Blood 2009; 114: 202030.
62 Lim W, Crowther MA, Eikelboom JW. Management of
antiphospholipid antibody syndrome: a systematic review.
JAMA 2006; 295: 105057.
63 Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of
secondary thromboprophylaxis in patients with antiphospholipid
antibodies. Arthritis Rheum 2007; 57: 148795.
64 Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two
intensities of warfarin for the prevention of recurrent thrombosis in
patients with the antiphospholipid syndrome. N Engl J Med 2003,
349: 113338.
65 Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical
trial of high-intensity warfarin vs. conventional antithrombotic
therapy for the prevention of recurrent thrombosis in patients with
the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;
3: 84853.
66 Levine SR, Brey RL, Tilley BC, et al, APASS Investigators.
Antiphospholipid antibodies and subsequent thrombo-occlusive
events in patients with ischemic stroke. JAMA 2004; 291: 57684.
67 Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin
and aspirin for the prevention of recurrent ischemic stroke.
N Engl J Med 2001; 345: 144451.
68 Garcia DA, Khamashta MA, Crowther MA. How we diagnose and
treat thrombotic manifestations of the antiphospholipid syndrome:
a case-based review. Blood 2007; 110: 312227.
69 Tektonidou MG, Ioannidis JPA, Boki KA, Vlachoyiannopoulos PG,
Moutsopoulos HM. Prognostic factors and clustering of serious
clinical outcomes in antiphospholipid syndome. Q J Med 2000;
93: 52330.
70 Danowski A, de Azevedo MN, de Souza Papi JA, Petri MA.
Determinants of risk for venous and arterial thrombosis in primary
antiphospholipid syndrome and in antiphospholipid syndrome with
systemic lupus erythematosus. J Rheumatol 2009; 36: 119599.
71 Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD.
A cross-sectional study of clinical thrombotic risk factors and
preventive treatments in antiphospholipid syndrome.
Rheumatology (Oxford) 2002; 41: 92429.
72 Martnez F, Forner MJ, Ruano M, Abdilla N, Oltra R,
Garca-Fuster MJ. [Factors related to the risk of thrombosis in
patients with lupus and antiphospholipid antibodies].
Med Clin (Barc) 2006; 127: 40508.
73 Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk
factors for thrombosis in 360 patients with antiphospholipid
antibodies: a four-year prospective study from the Italian registry.
Am J Med 1996; 100: 53036.
74 Quenby S, Farquharson RG, Dawood F, Hughes AM, Topping J.
Recurrent miscarriage and long-term thrombosis risk:
a case-control study. Hum Reprod 2005; 20: 172932.
75 Girn-Gonzlez JA, Garca del Rio E, Rodriguez C,
Rodriguez-Martorell J, Serrano A. Antiphospholipid syndrome and
asymptomatic carriers of antiphospholipid antibody: prospective
analysis of 404 individuals. J Rheumatol 2004; 31: 156067.
76 Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis
prevention in the antiphospholipid syndrome: a randomized,
double-blind, placebo-controlled trial in asymptomatic
antiphospholipid antibody-positive individuals. Arthritis Rheum
2007; 56: 238291.
77 Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E.
Analysis of risk factors for the development of thrombotic
complications in antiphospholipid antibody positive lupus patients.
Lupus 2007; 16: 3945.
78 Hereng T, Lambert M, Hachulla E, et al. Inuence of aspirin on the
clinical outcomes of 103 anti-phospholipid antibodies-positive
patients. Lupus 2008; 17: 1115.
79 Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP.
Prophylactic antithrombotic therapy for patients with systemic
lupus erythematosus with or without antiphospholipid antibodies.
Arch Intern Med 2000; 160: 204248.
80 Cervera R, CAPS Registry Project Group. Catastrophic
antiphospholipid syndrome (CAPS): update from the CAPS
Registry. Lupus 2010; 19: 41218.
81 Bramham K, Hunt BJ, Germain S, et al. Pregnancy outcome in
dierent clinical phenotypes of antiphospholipid syndrome.
Lupus 2010; 19: 5864.
82 Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: ten
questions and some answers. Lupus 2008; 17: 41620.
83 Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, et al. The second
trimester Doppler ultrasound examination is the best predictor of late
pregnancy outcome in systemic lupus erythematosus and/or the
antiphospholipid syndrome. Rheumatology (Oxford) 2006; 45: 33238.
84 Carmona F, Font J, Azulay M, et al. Risk factors associated with
fetal losses in treated antiphospholipid syndrome pregnancies:
a multivariate analysis. Am J Reprod Immunol 2001; 46: 27479.
85 Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG,
Ragin A. Comparative trial of prednisone plus aspirin versus
aspirin alone in the treatment of anticardiolipin antibody-positive
obstetric patients. Am J Obstet Gynecol 1993; 169: 141117.
86 Cowchock FS, Reece EA, Balaban D, Branch DW, Ploue L.
Repeated fetal losses associated with antiphospholipid antibodies:
a collaborative randomized trial comparing prednisone with
low-dose heparin. Am J Obstet Gynecol 1992; 166: 131823.
87 Triolo G, Ferrante A, Ciccia F, et al. Randomized study of
subcutaneous low molecular weight heparin plus aspirin versus
intravenous immunoglobulin in the treatment of recurrent fetal
loss associated with antiphospholipid antibodies. Arthritis Rheum
2003; 48: 72831
88 Branch DW, Peaceman AM, Druzin M, et al. A multicenter,
placebo-controlled pilot study of intravenous immune globulin
treatment of antiphospholipid syndrome during pregnancy.
Am J Obstet Gynecol 2000; 182: 12227.
89 Vaquero E, Lazzarin N, Valensise H, et al. Pregnancy outcome in
recurrent spontaneous abortion associated with antiphospholipid
antibodies: a comparative study of intravenous immunoglobulin
versus prednisone plus low-dose aspirin. Am J Reprod Immunol
2001; 45: 17479.
90 Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent
miscarriage for women with antiphospholipid antibody or lupus
anticoagulant. Cochrane Database Syst Rev 2005; 18: CD002859.
91 Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous
thromboembolism, thrombophilia, antithrombotic therapy, and
pregnancy: American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines (8th edn). Chest 2008; 133: 844S86S.
92 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of
aspirin and aspirin plus heparin in pregnant women with recurrent
miscarriage associated with phospholipid antibodies (or
antiphospholipid antibodies). BMJ 1997; 314: 25357.
93 Farquharson RG, Quenby S, Greaves M. Antiphospholipid
syndrome in pregnancy: a randomized, controlled trial of treatment.
Obstet Gynecol 2002; 100: 40813.
94 Laskin CA, Spitzer K, Clark C, et al. Low molecular weight heparin
and aspirin for recurrent pregnancy loss: results from the
randomized, controlled HepASA trial. J Rheumatol 2009; 36: 27987.
95 Kutteh WH. Antiphospholipid antibody-associated recurrent
pregnancy loss: treatment with heparin and low-dose aspirin is
superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;
174: 158489.
96 Noble LS, Kutteh WH, Lashey N, et al. Antiphospholipid antibodies
associated with recurrent pregnancy loss: prospective, multicenter,
controlled pilot study comparing treatment with low-molecular-
weight heparin versus unfractionated heparin. Fertil Steril 2005;
83: 68490.
Seminar
www.thelancet.com Vol 376 October 30, 2010 1509
97 Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of
antiphospholipid antibody syndrome (APS) in pregnancy: a
randomized pilot trial comparing low molecular weight heparin to
unfractionated heparin. J Obstet Gynaecol Can 2004; 26: 72934.
98 Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddel HS,
McDougall J. Does aspirin have a role in improving pregnancy
outcome for women with the antiphospholipid syndrome? A
randomized controlled trial. Am J Obstet Gynecol 2000; 183: 100812.
99 Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ,
Hughes GRV. A study of sixty pregnancies in patients with the
antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14: 13136.
100 Granger KA, Farquharson RG. Obstetric outcome in
antiphospholipid syndrome. Lupus 1997; 6: 50913.
101 Huong DLT, Wechsler B, Bletry O, et al. A study of 75 pregnancies
in patients with antiphospholipid syndrome. J Rheumatol 2001;
28: 202530.
102 Muoz-Rodriguez FJ, Font J, Cervera R, et al. Clinical study of
100 patients with the antiphospholipid syndrome.
Semin Arthritis Rheum 1999; 29: 18290.
103 Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, on behalf of
the PARIS Collaborative Group. Antiplatelet agents for prevention
of pre-eclampsia: a meta-analysis of individual patient data. Lancet
2007; 369: 179198.
104 stensen M, Khamashta M, Lockshin M, et al. Anti-inammatory
and immunosuppressive drugs and reproduction. Arthritis Res Ther
2006; 8: 20927.
105 Ruiz-Irastorza G, Khamashta MA, Hughes GR. Antiaggregant and
anticoagulant therapy in systemic lupus erythematosus and
Hughes syndrome. Lupus 2001; 10: 24145.
106 ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ,
Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin
alone after cerebral ischaemia of arterial origin (ESPRIT):
randomised controlled trial. Lancet 2006; 367: 166573.
107 ACTIVE Investigators. Eect of clopidogrel added to aspirin in
patients with atrial brillation. N Engl J Med 2009; 360: 206678.
108 Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs:
American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines (8th edn). Chest 2008; 133: 234S56S.
109 Connolly SJ, Ezekowitz MD, Yusuf S, et al, the RE-LY Steering
Committee and Investigators. Dabigatran versus warfarin in
patients with atrial brillation. N Engl J Med 2009; 361: 113951.
110 Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus
warfarin in the treatment of acute venous thromboembolism.
N Engl J Med 2009; 361: 234252.
111 Ramos-Casals M, Brito-Zern P, Muoz S, et al, BIOGEAS STUDY
Group. A systematic review of the o-label use of biological
therapies in systemic autoimmune diseases. Medicine (Baltimore)
2008; 87: 34564.
112 Brey RL. New treatment option for the antiphospholipid antibody
syndrome? More pleiotropic eects of the statin drugs.
J Thromb Haemost 2004; 2: 155657.
113 Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the
thrombogenic and inammatory properties of antiphospholipid
antibodies by uvastatin in an in vivo animal model.
Arthritis Rheum 2003; 48: 327279.
114 Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits
up-regulation of tissue factor expression by antiphospholipid
antibodies on endothelial cells. J Thromb Haemost 2004;
2: 155863.
115 Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial
cell activation induced by antiphospholipid (anti-beta2-glycoprotein I)
antibodies: eect on the proadhesive and proinammatory
phenotype. Arthritis Rheum 2001; 44: 287078.
116 Jajoria P, Murthy V, Papalardo E, Romay-Penabad Z, Gleason C,
Pierangeli SS. Statins for the treatment of antiphospholipid
syndrome? Ann N Y Acad Sci 2009; 1173: 73645.
117 Adams R, Albers GW, Alberts M, et al. Update to the AHA/ASA
recommendations for the prevention of stroke in patients with
stroke and transient ischemic attack. Stroke 2008; 39: 164752.
118 Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of
rosuvastatin in the prevention of venous thromboembolism.
N Engl J Med 2009; 360: 185161.
119 Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P,
Khamashta MA. Clinical e cacy and side eects of antimalarials
in systemic lupus erythematosus: a systematic review.
Ann Rheum Dis 2010; 69: 2028.
120 Kaiser R, Cleveland C, Criswell L. Risk and protective factors for
thrombosis in systemic lupus erythematosus: results from a large,
multi-ethnic cohort. Ann Rheum Dis 2009; 68: 23841.
121 Espinola RG, Pierangeli SS, Gharavi AE, Harris EN.
Hydroxychloroquine reverses platelet activation induced by human
IgG antiphospholipid antibodies. Thromb Haemost 2002;
87: 51822.
122 Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G,
Harris EN. Hydroxychloroquine reverses thrombogenic properties
of antiphospholipid antibodies in mice. Circulation 1997;
96: 438084.
123 Rand J, Wu X, Quinn A, Chen P, Hathcock J, Taatjes D.
Hydroxychloroquine directly reduces the binding of
antiphospholipid antibody-2-glycoprotein I complexes to
phospholipid bilayers. Blood 2008; 112: 168795.
124 Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the
annexin A5 anticoagulant shield from disruption by
antiphospholipid antibodies: evidence for a novel eect for an old
antimalarial drug. Blood 2010; 115: 229299.
Reproducedwith permission of thecopyright owner. Further reproductionprohibited without permission.